Patient-Reported Outcomes Following Initiation or Simplification of Treatment With iGlarLixi in Adults With Type 2 Diabetes: A Narrative Review.

Authors

Francesco Giorgino, Martin Haluzík, Agustina Alvarez, Felipe Lauand, Valérie Corp Dit Genti, Samir H Assaad-Khalil, Hemant Thacker, Tomasz Klupa, Oguzhan Deyneli, Julio Rosenstock

Published in

Diabetes, obesity & metabolism. Oct 19, 2026. Epub Oct 19, 2026.

Abstract

Given the significant burden that diabetes self-management poses, it is important to assess patient-reported outcomes (PROs) for Type 2 diabetes (T2D) treatments in clinical trials and real-world studies. Complex insulin regimens are associated with increased risk of hypoglycaemia and body weight gain, which could negatively impact treatment adherence and, therefore, achievement of glycaemic targets. iGlarLixi is a once-daily fixed-ratio combination of insulin glargine 100 U/mL and the glucagon-like peptide-1 receptor agonist (GLP-1 RA), lixisenatide. iGlarLixi is an effective treatment alternative to complex insulin regimens, with a favourable between-group difference in body weight and reduced risk of hypoglycaemia.
This is the first review to summarise data from multiple validated PRO measures for recent iGlarLixi studies (Soli-CGM, SoliMix, Soli-SWITCH, IDEAL, SUCCESS and SIMPLIFY JP), including: Global Treatment Effectiveness Evaluation, Audit of Diabetes Dependent Quality of Life, Diabetes Medication Satisfaction Tool, Diabetes Therapy-Related Quality of Life, Diabetes Treatment Satisfaction Questionnaire, Hypoglycaemic Attitudes and Behaviour Scale and Treatment-Related Impact Measure Diabetes.
In clinical studies, once-daily iGlarLixi was associated with numerical improvements in selected treatment satisfaction measures in those who switched from: complex insulin regimens (once- or twice-daily premixed insulin and basal-bolus insulin), basal insulin or oral glucose-lowering medications. Additionally, in real-world studies, iGlarLixi was generally associated with improvements in treatment satisfaction and quality of life outcomes in adults with T2D who previously received basal-bolus insulin or oral glucose-lowering medications ± basal insulin or GLP-1 RAs.
In conclusion, a once-daily injection of iGlarLixi may offer a clinically beneficial, simplified treatment option for adults with T2D compared with complex insulin-based regimens.

PMID:
42897097
Bibliographic data and abstract were imported from PubMed on 20 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.